Immuron Stock

Immuron Revenue

The The revenue of Immuron (IMC.AX) as of Aug 24, 2026 is 7.29 M AUD. In the previous year, The revenue was 4.90 M AUD — a change of 48.63% (higher).

Revenue

7.29 MAUD

YoY

48.63%

Last updated:

In 2026, Immuron's sales reached 7.29 M AUD, a 48.63% difference from the 4.90 M AUD sales recorded in the previous year.

Revenue has compounded at 2.2% per year over the past 19 years to 7.29 M AUD.

The Immuron Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2018
3.69 M AUD
Jan 1, 2019
2.39 M AUD
Jan 1, 2020
2.52 M AUD
Jan 1, 2021
145,800.00 AUD
Jan 1, 2022
765,200.00 AUD
Jan 1, 2023
1.80 M AUD
Jan 1, 2024
4.90 M AUD
Jan 1, 2025
7.29 M AUD
The Immuron Revenue history
YEARRevenueYoY
7.29 MAUD+48.63%
4.90 MAUD+171.67%
1.80 MAUD+135.85%
765,200.00AUD+424.83%
145,800.00AUD-94.21%
2.52 MAUD+5.50%
2.39 MAUD-35.36%
3.69 MAUD+23.94%
2.98 MAUD-25.43%
4.00 MAUD+255.60%
1.12 MAUD+8.05%
1.04 MAUD+593.33%
150,000.00AUD-67.39%
460,000.00AUD+53.33%
300,000.00AUD-40.00%
500,000.00AUD-9.09%
550,000.00AUD-49.54%
1.09 MAUD-79.04%
5.20 MAUD+8.11%
4.81 MAUD
Access this data via the Eulerpool API

Immuron Revenue

Immuron Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
3.69 M AUD
-2.83 M AUD
-3.01 M AUD
Jan 1, 2019
2.39 M AUD
-4.69 M AUD
-4.66 M AUD
Jan 1, 2020
2.52 M AUD
-3.07 M AUD
-2.93 M AUD
Jan 1, 2021
145,800.00 AUD
-7.20 M AUD
-8.38 M AUD
Jan 1, 2022
765,200.00 AUD
-3.12 M AUD
-2.85 M AUD
Jan 1, 2023
1.80 M AUD
-3.44 M AUD
-3.79 M AUD
Jan 1, 2024
4.90 M AUD
-5.24 M AUD
-6.94 M AUD
Jan 1, 2025
7.29 M AUD
-5.36 M AUD
-5.22 M AUD

Immuron Margins

Immuron stock margins

The Immuron margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immuron. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immuron.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
88.66 %
-76.58 %
-81.52 %
Jan 1, 2019
72.05 %
-196.65 %
-195.04 %
Jan 1, 2020
72.65 %
-121.96 %
-116.22 %
Jan 1, 2021
64.95 %
-4,937.72 %
-5,750.69 %
Jan 1, 2022
68.41 %
-407.40 %
-373.01 %
Jan 1, 2023
96.42 %
-190.44 %
-209.81 %
Jan 1, 2024
68.06 %
-106.95 %
-141.49 %
Jan 1, 2025
65.39 %
-73.51 %
-71.58 %

Immuron Stock analysis

What does Immuron do? Immuron Ltd was founded in 1994 and is headquartered in Melbourne, Australia. The company specializes in researching, developing, and marketing immunotherapy products. Immuron utilizes its patented technologies to develop and manufacture polyclonal antibodies and hyperimmune serums. The business model of Immuron focuses on selling immunotherapy products. The company concentrates on developing innovative products that address high medical needs and significantly improve the health of patients. Immuron operates in three divisions: gastrointestinal health, veterinary medicine, and infection control. Within these divisions, Immuron offers a variety of products tailored to specific needs. Gastrointestinal health is one of Immuron's key divisions. The company utilizes its expertise to develop products that protect and strengthen the human and animal intestine. Products in the gastrointestinal division include Travelan®, which is used for the prevention and treatment of traveler's diarrhea, and IMM-124E, which is used to treat inflammatory bowel diseases. It is also available in veterinary medicine. Veterinary medicine is another important pillar of Immuron's business. The company offers products tailored to the needs of animals. One notable product is the Immuron Canine® product line, used in the treatment of diarrhea in dogs. Additionally, the company has developed application-oriented research programs in infection control to aid veterinarians in improving the health of their animals. Immuron also has a division focused on infection control. The company develops and manufactures therapeutic products that target infections such as Helicobacter pylori and C. difficile. These products can contribute to reducing the use of antibiotics and antibiotic resistance. Over the years, Immuron has successfully brought several products to market. For example, Travelan® has been approved in Australia, Europe, and North America. Additionally, IMM-124E has been successfully tested in clinical studies in Canada and the United States and is currently undergoing the approval process in Europe. Overall, the company has a promising pipeline of products ready for market launch or phase II and III trials. These products have the potential to improve healthcare and enhance the quality of life for patients worldwide. Immuron has a strong foundation in immunotherapy research, which benefits the company in developing novel therapeutic options. Currently, Immuron is in a phase of growth, and it is likely that the company will achieve further success in the future. Immuron is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Immuron's Sales Figures

The sales figures of Immuron originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Immuron’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Immuron's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Immuron’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Immuron stock

The revenue of Immuron is 7.29 M AUD in 2026.

The revenue of Immuron changed from 4.90 M AUD to 7.29 M AUD, representing a 48.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Immuron since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Immuron historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Immuron

All Key Metrics — Immuron